Profile data is unavailable for this security.
About the company
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
- Revenue in USD (TTM)0.00
- Net income in USD-9.67m
- Incorporated2014
- Employees11.00
- LocationCocrystal Pharma Inc19805 N Creek PkwyBOTHELL 98011-8251United StatesUSA
- Phone+1 (786) 459-1831
- Fax+1 (302) 636-5454
- Websitehttps://www.cocrystalpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioCardia Inc | 0.00 | -8.54m | 12.10m | 17.00 | -- | 4.60 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.33m | 82.00 | -- | 0.3542 | -- | 1.32 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.36m | 1.00 | -- | 0.9355 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.45m | 1.00 | -- | 1.62 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| TRON Group Inc | 1.01m | -549.47k | 12.51m | 50.00 | -- | -- | -- | 12.39 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 12.63m | 1.00 | -- | 0.4081 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 12.78m | -- | -- | 0.1433 | -- | 5.06 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 12.94m | 4.00 | -- | 4.17 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 13.30m | 11.00 | -- | 1.64 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 13.41m | 85.00 | -- | 2.86 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.59m | 6.00 | -- | 1.13 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.62m | 17.00 | -- | 5.69 | -- | 3.49 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 14.64m | 9.00 | -- | -- | -- | 37.55 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 239.97k | 1.74% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 126.03k | 0.91% |
| Geode Capital Management LLCas of 31 Dec 2025 | 82.50k | 0.60% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 73.75k | 0.54% |
| DRW Securities LLCas of 31 Dec 2025 | 33.59k | 0.24% |
| Neuberger Berman Investment Advisers LLCas of 31 Dec 2025 | 31.89k | 0.23% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 24.02k | 0.17% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 20.54k | 0.15% |
| Parallel Advisors LLCas of 31 Dec 2025 | 12.57k | 0.09% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 11.92k | 0.09% |
